FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     McGuinness Michael					2. Issuer Name and Ticker or Trading Symbol MANHATTAN PHARMACEUTICALS INC [ MHA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last) (First) (Middle) 810 SEVENTH AVENUE, 4TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 07/10/2006							X below) below)  Chief Financial Officer					
(Street) NEW Y(		Y tate)	10019 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Lir	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(- 9)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date				Transacti ate			3. Transac	3. 4. Securities Acquired (A) Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			red (A) or	5. Amou Securitie Benefici	s ally following	Form:	Direct Indirect Itr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) (D)	or Price	Transaci (Instr. 3	ion(s)				
Common Stock													0		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. )		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	(0)		
Stock Options <sup>(1)</sup>	\$0.7	07/10/2006		A		220,000		(2)	07	7/10/2016	Common Stock	220,000	\$0	220,00	00	D	
Stock Options <sup>(1)</sup>	\$1.35	07/10/2006		A		60,000		(3)	07	7/10/2016	Common Stock	60,000	\$0	60,00	0	D	

## Explanation of Responses:

- 1. Pursuant to Section 16b-3 (right to buy).
- 2. Option vests as follows: 73,334 shares on 7/10/07 and 73,333 shares each on 7/10/08 and 7/10/09.
- 3. 20,000 shares vest on each of 7/10/07, 7/10/08 and 7/10/09.

/s/ Michael McGuinness 07/11/2006

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.